"Inflammatory Carcinoma" of the Breast

Taylor, Grantley W.; Meltzer, Adolph

doi:10.1158/ajc.1938.33

Cited by 135 publications

(65 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pathologically, IBC is frequently diagnosed by the presence of cancer cells penetrating dermal lymphatic channels causing the inflammatory signs [6]. The management of IBC has evolved over the past 30 years.…”

Section: Introductionmentioning

confidence: 99%

Trends for Inflammatory Breast Cancer: Is Survival Improving?

et al. 2007

View full text Add to dashboard Cite

The purpose of this study was to evaluate whether the survival of women with inflammatory breast cancer (IBC) treated at our institution has improved over the past 30 years. Three-hundred ninety-eight patients with IBC were treated between 1974 and 2005. Patient characteristics and outcomes were tabulated and compared among decades of diagnosis. Survival outcomes were estimated with the Kaplan-Meier product limit method and compared among groups with the log-rank statistic. Cox proportional hazards models were fit to determine the association between year of diagnosis and survival outcomes after adjustment for patient and disease characteristics and treatments received. The median follow-up was 5. Disclosure of potential conflicts of interest is found at the end of this article.

show abstract

Section: Introductionmentioning

confidence: 99%

Trends for Inflammatory Breast Cancer: Is Survival Improving?

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Pathologically, IBC is frequently diagnosed by the presence of cancer cells penetrating dermal lymphatic channels ( Fig. 1), causing the inflammatory signs (6).…”

Section: Introductionmentioning

confidence: 99%

p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer

González-Angulo¹,

Sneige²,

Buzdar³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. Nuclear expression of p53 protein in breast cancer correlates with more aggressive tumors. We retrospectively analyze the expression of p53 as a prognostic marker to predict pathological complete response and survival in patients with IBC.Experimental Design: Fifty-nine patients with IBC were treated from January 1994 to April 2000. Forty-eight patients were included. Diagnostic core biopsies were taken before treatment was started. Expression of hormone receptors and p53 was determined by immunohistochemistry. All patients received an anthracycline-based regimen preoperatively; 22 patients (46%) also received paclitaxel. Fortyfour patients (92%) achieved an objective clinical response and underwent mastectomies.Results: Median age at diagnosis was 48 years. Thirty patients (63%) had hormone receptor-negative tumors. Twenty-eight patients (58%) had p53-positive tumors, and 20 patients (42%) had p53-negative tumors. Nine patients (19%) achieved a pathological complete response. At a median follow-up of 77 months, 28 recurrences (58%) and 26 deaths (54%) had occurred. Patients with p53-positive tumors were younger (P ‫؍‬ 0.02) and tended to have lower 5-year progression-free survival rates (35% versus 55%; P ‫؍‬ 0.3) and overall survival rates (44% versus 54%; P ‫؍‬ 0.4).Conclusions: This retrospective analysis demonstrates that nuclear p53 protein expression may represent an adverse prognostic marker in IBC and may provide a valuable tool for selecting treatment for this aggressive disease.

show abstract

“…Taylor and Meltzer described this peculiar type of skin metastasis for the first time in 1938 [2]. Its name belongs from the Latin "coriaceous" that means made of leather, from corium, the original breastplate of ancient warriors.…”

Section: Discussionmentioning

confidence: 99%